Frances Platt

Platt was interested in insects as a child. Her father was a general practitioner.[2] Platt was an undergraduate student at Imperial College London, where she majored in zoology.[2] She moved to the University of Bath for her graduate studies. Her doctoral research looking at the impact of monoclonal antibodies on the prothoracic glands of Manduca sexta.[3] Platt was a postdoctoral researcher at the Washington University School of Medicine, where she investigated how abnormal accumulation of glycosphingolipids.[4] During her final year, her boss moved to the pharmaceutical arm of Monsanto, where Platt became aware of industrial research and antiviral drugs.[2]

In 1996, Platt was appointed as a senior research fellow at the Lister Institute of Preventive Medicine. She moved to the University of Oxford in 2006, where she was named Head of the Department of Pharmacology in 2020.[5]

Platt studies genetic disorders known as lysosomal storage diseases.[1] The lysosome is a compartment within cells that is involved with breaking down large molecules. When it goes wrong, molecules accumulate in the lysosome (so-called “storage,”). Specifically, Platt is particularly interested in the build up of sphingolipids, the build-up of which can cause neurodegeneration.[6] Platt looks to better understand these conditions as well as developing novel therapeutic pathways.[4] In particular, Platt developed substrate reduction therapies.[4]

Platt identified that a drug she was investigating as an antiviral was effective in treating lysosomal diseases. She managed to get the drug (Miglustat) approved by the European Medicines Agency and Food and Drug Administration for the treatment of both Gaucher's disease and Niemann–Pick disease.[7]

Platt has two children.[2]